Skyrocketing Drug Prices: What's Driving Up Costs?
Prescription drugs treat conditions and improve patient health. But when drug prices are too high, access to medicines becomes out of reach for far too many patients.
AAM Issue Brief: Biosimilars Medicare Part B
The Biosimilars Council Opposes Efforts to Prohibit Biosimilars From Receiving Pass-Through Status in the Medicare Part B Program
Despite the importance of biosimilars to reducing the cost of medicine, policymakers recently included a provision in a proposed bill that would have prohibited biosimilars from receiving pass-through status in Medicare Part B.
2017 AAM Annual Report
2017 Was Epic
The landscape around us looks much different today than it did just one year ago. As our industry changes within the evolving pharmaceutical ecosystem, we must speak with one voice to drive home the message that a robust generic drug and biosimilars marketplace is necessary to sustain affordable health care.
AAM White Paper: Ensuring the Future of Accessible Medicines in the U.S.
Patient health and well-being depends on the uninterrupted availability of lower-cost generic and biosimilar medicines. Moreover, as patients live longer the importance of a robust and sustainable generic and biosimilar medicines industry becomes only that much more important. Policymakers must act quickly to ensure continued saving and market-based competition, as well as prevent shortages, for future availability of affordable medicines. This requires:
AAM and the Biosimilars Council Call on Congress to Increase Patient Access to Biosimilars
Short-term CR adds biosimilars to Part D, but discourages biosimilar adoption in Part B
7 Policy Solutions
Association for Accessible Medicines is calling on Congress to take meaningful action to lower prescription drug costs with the Prescription for Savings. Patients win when market-based competition from FDA-approved generics and biosimilars deliver savings at the pharmacy counter.
To this end, we recommend these seven policy solutions:
AAM Issue Brief: Biosimilars Medicare Part D
Increasing Patient Access to Biosimilars in Medicare Part D
Congress should amend the Part D coverage gap discount program to classify biosimilars as “applicable drugs” in the Coverage Gap Discount Program. This change would allow biosimilar manufacturers to pay the 50 percent discounts paid by their brand competitors, and participate on a level playing field to compete for placement on the Part D plan’s formulary. It would reduce both patient out-of-pocket costs and Part D program spending.
AAM Tells Senate: Generics Are Solution to High Drug Prices
On October 17, 2017, the Senate Health, Education, Labor and Pensions Committee, under the leadership of Senators Lamar Alexander (R-TN) and Patty Murray (D-WA), convened a hearing to explore why drug prices are so high. The committee asked trade associations representing different parts of the prescription drug supply chain – manufacturers, wholesalers, pharmacy benefits managers and pharmacists – to help it understand what can be done to provide some relief for the millions of Americans burdened by skyrocketing prescription drug costs.
New Report Indicates Revising CMS Policy on Biosimilars Could Save $11.4 Billion On Medicines Over 10 Years
WASHINGTON, DC (September 19, 2017) — Today, the Association for Accessible Medicines (AAM) and its Biosimilars Council released an analysis finding that if the Centers for Medicare & Medicaid Services (CMS) were to revise its current reimbursement policy for biosimilar medicines, the federal government could save $11.4 billion on medicines over the next 10 years.
Five Reasons Why It’s Time to Lead on Biosimilars
September is nearly upon us, and registration is open for the Association for Accessible Medicines (AAM) and its Biosimilars Council’s 2017 two-day conference – Leading on Biosimilars, taking place on September 12 & 13 in Washington, D.C. The conference will feature presentations from key industry leaders, U.S. Government agency officials, and academic experts regarding the dynamic landscape of the biosimilars industry.